Aricept News and Research

RSS
The hydrochloride salt of a piperidine derivative with neurocognitive-enhancing activity. Donepezil (Aricept) reversibly inhibits acetylcholinesterase, thereby blocking the hydrolysis of the neurotransmitter acetylcholine and, consequently, increasing its activity. This agent may improve neurocognitive function in Alzheimer's disease, reduce sedation associated with opioid treatment of cancer pain, and improve neurocognitive function in patients who have received radiation therapy for primary brain tumors or brain metastases. Donepezil (Aricept) is the most prescribed Alzheimer's disease therapy worldwide.
Alzheimer's drug prescribed off-label could accelerate cognitive decline for some patients

Alzheimer's drug prescribed off-label could accelerate cognitive decline for some patients

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

More research needed before recommending antidepressants, Alzheimer's disease drugs for stroke recovery: Study

First patients screened in Axovant's phase 3 study of RVT-101

First patients screened in Axovant's phase 3 study of RVT-101

New drug shows promise in slowing Alzheimer’s disease

New drug shows promise in slowing Alzheimer’s disease

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Nicotine metabolite supports learning, memory by amplifying action of primary chemical messenger

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Study: Prostate cancer drug stabilizes memory loss for a year in women with Alzheimer's disease

Alzheimer's drug Aricept (donepezil) linked to serious side effects

Alzheimer's drug Aricept (donepezil) linked to serious side effects

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

FDA approves Namzaric drug for treatment of moderate to severe Alzheimer's disease

Anavex Life Sciences qualifies to trade on OTCQX

Anavex Life Sciences qualifies to trade on OTCQX

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

Neuronetrix selected to support upcoming ANAVEX 2-73 Phase 2a clinical trial

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

TWi Pharmaceuticals obtains final ANDA approval for Donepezil Hydrochloride Tablets USP, 23 mg

Investigational drug focuses on slowing Alzheimer's disease progression

Investigational drug focuses on slowing Alzheimer's disease progression

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Eisai collaborates with Biogen Idec to develop and commercialize treatment options for AD

Research findings may pave way to new treatment for Alzheimer's disease in humans

Research findings may pave way to new treatment for Alzheimer's disease in humans

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Anavex invited to submit funding application for Phase 2a trial of ANAVEX 2-73

Scientists demonstrate new approach for quickly assembling drug-like compounds

Scientists demonstrate new approach for quickly assembling drug-like compounds

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

Ginkgo biloba supplements fail to improve cognitive performance in multiple sclerosis

ASS234 molecule inhibits aggregation of the Alzheimer's protein

ASS234 molecule inhibits aggregation of the Alzheimer's protein

TPU, Eisai amend Aricept patch licensing agreement

TPU, Eisai amend Aricept patch licensing agreement

Patients with advanced Alzheimer’s benefit from drugs: Study finds

Patients with advanced Alzheimer’s benefit from drugs: Study finds